Operating Segments (Tables)

9 Months Ended

Sep. 30, 2022

Operating Segments

Schedule of operating segments

	Three Months Ended
	September 30,
	2022		2021
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		166,140		186,198
Total	$	166,140	$	186,198
Loss from Operations
Specialized BioTherapeutics	$	(1,856,553)	$	(2,034,507)
Public Health Solutions		(9,578)		(160,970)
Corporate		(1,215,113)		(1,169,434)
Total	$	(3,081,244)	$	(3,364,911)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,876	$	1,883
Public Health Solutions		479		314
Corporate		1,438		6,678
Total	$	4,793	$	8,875
Other (Expense) Income, Net
Specialized BioTherapeutics	$	(12,613)	$	(26,123)
Corporate		(215,146)		(196,517)
Total	$	(227,759)	$	(222,640)
Share-Based Compensation
Specialized BioTherapeutics	$	28,343	$	28,506
Public Health Solutions		1,054		6,518
Corporate		41,318		44,697
Total	$	70,715	$	79,721

	Nine Months Ended
	September 30,
	2022		2021
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		582,843		548,615
Total	$	582,843	$	548,615
Loss from Operations
Specialized BioTherapeutics	$	(5,396,630)	$	(4,867,481)
Public Health Solutions		(131,201)		(399,512)
Corporate		(5,141,095)		(3,320,184)
Total	$	(10,668,926)	$	(8,587,177)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	8,273	$	5,644
Public Health Solutions		1,379		941
Corporate		11,886		20,029
Total	$	21,538	$	26,614
Other (Expense) Income, Net
Specialized BioTherapeutics	$	110,975	$	99,512
Corporate		(641,768)		(224,174)
Total	$	(530,793)	$	(124,662)
Share-Based Compensation
Specialized BioTherapeutics	$	85,190	$	86,816
Public Health Solutions		3,162		20,002
Corporate		132,304		148,329
Total	$	220,656	$	255,147

	As of		As of
	September 30,		December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	121,567	$	128,645
Public Health Solutions		137,910		146,296
Corporate		17,687,896		26,594,986
Total	$	17,947,373	$	26,869,927